The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Jan. 31, 2024
Applicant:

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Greg Dussor, Dallas, TX (US);

Jacob E. Lackovic, Dallas, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/05 (2006.01); A61K 31/167 (2006.01); A61K 31/19 (2006.01); A61K 31/343 (2006.01); A61K 31/426 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/05 (2013.01); A61K 31/167 (2013.01); A61K 31/19 (2013.01); A61K 31/343 (2013.01); A61K 31/426 (2013.01);
Abstract

The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide, eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.


Find Patent Forward Citations

Loading…